64 results on '"Morton, G"'
Search Results
2. A Randomized Phase II Trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) Brachytherapy as Monotherapy in Localized Prostate Cancer: Analysis of Initial Arms of Canadian Cancer Trials Group PR19 (NCT02960087)
3. Ultrahypofractionated vs. Moderately Hypofractionated and Conventionally Fractionated Pelvic Radiotherapy for Prostate Cancer: Outcomes from 3 Prospective Clinical Trials
4. Dosimetric Parameters Predictive of Treatment-Related Toxicity in High Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer
5. Dosimetric Predictors of Toxicities and Quality of Life Following Two-Fraction Stereotactic Body Radiotherapy for Prostate Cancer
6. Long-Term Outcomes of NRG/RTOG 0126, a Randomized Trial of High Dose (79.2 Gy) vs. Standard Dose (70.2 Gy) Radiation Therapy (RT) for Men with Localized Prostate Cancer
7. Salvage Prostate Brachytherapy in Radiorecurrent Prostate Cancer: An International Delphi Consensus Study
8. Five-Fraction Stereotactic Ablative Radiotherapy to the Pelvis and Prostate with Focal Intra-Prostatic Boost: Outcomes of the 5STAR Trial
9. Elective Nodal Ultra Hypofractionated Radiation for Prostate Cancer: Safety and Efficacy From Four Prospective Clinical Trials
10. Elective Pelvic Nodal Irradiation With A Simultaneous Hypofractionated Integrated Prostate Boost for Localized High Risk Prostate Cancer: Long Term Results From a Prospective Clinical Trial
11. Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial
12. Dose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized Trial
13. A Prospective Study of MR-Guided Focal Salvage High Dose-Rate Brachytherapy for Radiorecurrent Prostate Cancer: Updated Results of 30 Patients
14. Dosimetric Predictors of Toxicity and Quality of Life Following Single Fraction High Dose-Rate Prostate Brachytherapy
15. Biochemical Failure and Toxicity of Magnetic Resonance Imaging Dose Painting to Dominant Intraprostatic Lesion in Prostate High Dose Rate Brachytherapy
16. Intermittent Androgen Deprivation Therapy Plus Comprehensive Stereotactic Radiotherapy for Oligometastatic Prostate Cancer (CROP)
17. Radiation Oncologist Consultations Prior to Prostatectomy: Disparities and Opportunities
18. Combined Whole Prostate Dose Escalation With Focal Gross Disease Boost Using 169Yb-Based Rotating Shield Brachytherapy
19. Is Prostate Brachytherapy a Dying Art? Evidence of Increasing Utilization in Ontario, Canada
20. Analysis of PSA Kinetics and Late Treatment Related Toxicity in a Phase 2 Randomized Pilot Study Comparing High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
21. High Dose-Rate Prostate Brachytherapy as Monotherapy: a Single Fraction May Not be Enough
22. A Patient-Centric, Systematic, Quantitative, and Visual Approach to Prostate Cancer Treatment Decision Making
23. Toxicity and Quality of Life Outcomes from a Randomized Phase II Trial of HDR Monotherapy for Low and Intermediate-Risk Prostate Cancer
24. Comprehensive Stereotactic Radiotherapy for Oligometastatic Prostate Cancer (CROP)
25. A Phase II Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Low-Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
26. Stereotactic Body Radiotherapy (SBRT) Boost to Mimic High-Dose Rate (HDR) Brachytherapy Boost for Intermediate Risk Prostate Cancer: A Phase 1 Study
27. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiation Therapy (NRG/RTOG0526): Initial Report of Late Toxicity Outcome
28. MRI guided Focal Boost Integrated with HDR Brachytherapy for Prostate Cancer Patients: A Dosimetric Analysis
29. Single 19-Gy High-Dose-Rate Brachytherapy Monotherapy for Treatment of Prostate Cancer: Tolerability and Dosimetric Predictors of Acute Toxicity and Health-Related Quality of Life
30. Empowering Patients Through Education—Development and Evaluation of a Multimedia Patient Education Tool to Ensure Patient Preparedness for Planning CT Scan for Prostate Cancer (Randomized Study)
31. Low-Dose-Rate Brachytherapy Versus Standard Fractionated External Beam Radiation Therapy Versus Stereotactic Body Radiation Therapy for Low-Risk Prostate Cancer: A Cost-Utility Analysis
32. Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost For Localized High-Risk Prostate Cancer: Five-Year Results of a Prospective Trial
33. Initial Results of a Phase 3 Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (RTOG 0126)
34. Comparison of Active Surveillance, Low-Dose-Rate Brachytherapy, Stereotactic Ablative Body Radiation Therapy, and Standard External Beam in Low-Risk Prostate Cancer
35. Stereotactic Body Radiation Therapy (SBRT) Boost to Mimic High-Dose-Rate (HDR) Brachytherapy for Intermediate-Risk Prostate Cancer: A Phase 1 Study
36. Stereotactic Radiation Therapy Versus External Beam + High-Dose-Rate Brachytherapy Boost in the Treatment of Localized Prostate Cancer: A Quality of Life Analysis
37. Concomitant Hypofractionated IMRT Boost for High-Risk Prostate Cancer: 5 Year Results
38. Comparison of Biochemical and Toxicity Outcomes From a Contemporaneous Cohort Study of Low-Risk Prostate Cancer Treated With Different Radiation Techniques
39. Dose Escalation of 5-Fraction Radiation Therapy for Prostate Cancer: Quality of Life Comparison of 2 Prospective Trials
40. Dose Volume Analysis of Grade 2+ Late GI Toxicity on RTOG 0126 After High-dose 3DCRT or IMRT
41. Patient Reported Outcomes after Hypofractionated Radiotherapy and Long-term Androgen Deprivation for High-risk Prostate Cancer
42. Long-term Results of an RTOG Phase II Trial (00-19) of External Beam Radiation Therapy Combined with Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate
43. Long Term Results of a Phase II Trial of Ultrasound-guided Radioactive Implantation of the Prostate for Definitive Management of Localized Adenocarcinoma of the Prostate (RTOG 98–05)
44. Prospective Study Evaluating Salvage Radiotherapy Plus 2-year Androgen Suppression for Post-radical Prostatectomy Patients with PSA Relapse
45. MP-3.05: Hypofractionated Accelerated Radiotherapy for Low-Risk Localized Prostate Cancer: The Further Follow-up of a Weekly Canadian Regimen
46. POS-03.113: Initial Canadian experience of hypofractionated accelerated radiotherapy for low risk localized prostate cancer (pHART 3)
47. Quality of Life After Combined Postoperative Adjuvant Radiotherapy and Androgen Suppression for Adenocarcinoma of the Prostate
48. Results of a prospective multi-institutional phase II trial (RTOG 98–05) of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate
49. Effect of androgen suppression (AS) on hemoglobin (HB) levels in prostate cancer patients undergoing post-operative adjuvant radiotherapy (RT) and 2-year as
50. Surveillance is a safe alternative to up-front post-operative adjuvant therapy for stage I testicular seminoma after radical inguinal orchiectomy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.